Toshi Menju
YOU?
Author Swipe
View article: Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells
Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells Open
Brain metastases are frequent and often lethal complications of advanced cancers. Microglia, resident immune cells of the brain, are known to exert both anti-tumor and pro-tumor functions in late-stage metastases; however, their response d…
View article: Pulmonary hyalinizing granuloma presenting with mixed imaging features in CT and FDG PET: A case report
Pulmonary hyalinizing granuloma presenting with mixed imaging features in CT and FDG PET: A case report Open
View article: M2-like tumor-associated macrophages may promote tumor progression in malignant pleural mesothelioma
M2-like tumor-associated macrophages may promote tumor progression in malignant pleural mesothelioma Open
View article: Pathological Features and Differential Efficacy of Cisplatin-Based Adjuvant Chemotherapy in Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations
Pathological Features and Differential Efficacy of Cisplatin-Based Adjuvant Chemotherapy in Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Open
Cisplatin-based adjuvant chemotherapy might be less effective in patients with EGFR-mutated lung cancer. The style of progression and histological pattern related with EGFR mutation may be associated with the efficacy of adjuvant chemother…
View article: ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Receptor and Activation of Nuclear Factor-Kappa B in Non-Small Cell Lung Cancer
ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Receptor and Activation of Nuclear Factor-Kappa B in Non-Small Cell Lung Cancer Open
AMAP1 may inversely regulate PD-L1 through negative feedback of pEGFR and activation of NF-κB in NSCLC cell lines.
View article: A stearate-rich diet and oleate restriction directly inhibit tumor growth via the unfolded protein response
A stearate-rich diet and oleate restriction directly inhibit tumor growth via the unfolded protein response Open
Fatty acids are known to have significant effects on the properties of cancer cells. Therefore, these compounds have been incorporated into therapeutic strategies. However, few studies have examined the effects of individual fatty acids an…
View article: Extended segmentectomy for intersegmental lesions with intraoperative surgical margin assessment by radiofrequency identification markers
Extended segmentectomy for intersegmental lesions with intraoperative surgical margin assessment by radiofrequency identification markers Open
Use of radiofrequency identification markers enabled precise extended segmentectomy with adequate surgical margins.
View article: Stearate-rich diet and oleate restriction directly inhibit tumor growth via the unfolded protein response
Stearate-rich diet and oleate restriction directly inhibit tumor growth via the unfolded protein response Open
Fatty acids are known to have a significant impact on the properties of cancer cells. Therefore, Incorporating them into therapeutic strategies has been reported. However, few studies have examined the effects of individual fatty acids and…
View article: Supplementary Figure S7 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S7 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S7 shows the relative expression of TEAD1 and CTGF in KTOR27 cells treated with afatinib with TEAD1 knockdown.
View article: Supplementary Table S6 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Table S6 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Table S6 shows HALO configuration settings for immunohistochemistry.
View article: Supplementary Table S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Table S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Table S1 shows antibodies used for immunoblotting.
View article: Supplementary Table S4 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Table S4 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Table S4 shows siRNA oligonucleotides.
View article: Data from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Data from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation–positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation–positive lung…
View article: Supplementary Figure S4 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S4 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S4 shows cell viability assays of KTOR27 cells treated with afatinib and verteporfin.
View article: Supplementary Table S5 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Table S5 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Table S5 shows antibodies used for immunohistochemical staining.
View article: Supplementary Figure S4 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S4 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S4 shows cell viability assays of KTOR27 cells treated with afatinib and verteporfin.
View article: Supplementary Data S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Data S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Data S1 shows the list of compound names and relative cell viability rates.
View article: Data from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Data from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation–positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation–positive lung…
View article: Supplementary Figure S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S1 shows the cell viability signal with or without the freezing and thawing procedure.
View article: Supplementary Table S5 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Table S5 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Table S5 shows antibodies used for immunohistochemical staining.
View article: Supplementary Figure S8 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S8 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S8 shows the cell growth assay of KTOR27 cells treated with afatinib with TEAD1 knockdown.
View article: Supplementary Figure S6 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S6 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S6 shows the relative expression of CTGF in KTOR27 cells treated with afatinib with YAP1 knockdown.
View article: Supplementary Figure S5 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S5 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S5 shows the relative expression of CYR61 in KTOR27 cells treated with afatinib with or without VT104.
View article: Supplementary Table S3 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Table S3 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Table S3 shows primers used for qRT-PCR.
View article: Supplementary Figure S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S1 shows the cell viability signal with or without the freezing and thawing procedure.
View article: Supplementary Table S4 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Table S4 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Table S4 shows siRNA oligonucleotides.
View article: Supplementary Figure S9 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S9 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S9 shows cell viability assays of PC9, HCC827, and H1975 cells treated with VT104.
View article: Supplementary Figure S11 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S11 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S11 shows immunofluorescent staining of H1975 cells treated with osimertinib.
View article: Supplementary Figure S5 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S5 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S5 shows the relative expression of CYR61 in KTOR27 cells treated with afatinib with or without VT104.
View article: Supplementary Figure S7 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer
Supplementary Figure S7 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer Open
Supplementary Figure S7 shows the relative expression of TEAD1 and CTGF in KTOR27 cells treated with afatinib with TEAD1 knockdown.